Uncertain risks of drug related harms, the precautionary principle and limitations of meta-analysis

British Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2009, Pages 647-650

  Ritter, Jm ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETORICOXIB; IBUPROFEN; INSULIN GLARGINE; LUMIRACOXIB; NAPROXEN; NATALIZUMAB; PARECOXIB; PLACEBO; ROFECOXIB; THROMBOXANE; VALDECOXIB;

BIOSTATISTICS; CANCER RISK; CARCINOGENICITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PHARMACOLOGY; CLINICAL RESEARCH; CREUTZFELDT JAKOB DISEASE; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HEART PROTECTION; HUMAN; LIVER FAILURE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STROKE; THROMBOGENESIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOGENS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 70449386912     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03553.x     Document Type: Editorial

References (28)

1. Hemkens LG et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogue: a cohort study. Diabetologia 2009 52 : 1732 1744.
2. Jonasson JM et al. Insulin glargine use and short-term incidence of malignancies - a population-based follow-up study in Sweden. Diabetologia 2009 52 : 1745 1754.
3. Colhoun HM SDRN epidemiology group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network epidemiology group. Diabetologia 2009 52 : 1755 1765.
4. Curry CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type II diabetes. Diabetologia 2009 54 : 1766 1777.
5. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetolgica 2009 52 : 1699 1708.
6. Gale EAM. Insulin glargine and cancer: another side to the story? Lancet 2009 374 : 521.
7. Pocock SJ, Sneeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009 374 : 511 513.
8. Asif J. General product safety law in The law and regulation of medicines (Feldschreiber P ed) 2008 Oxford University Press.
9. Aronson JK. The NSAID rollercoaster - more about rofecoxib. Br J Clin Pharmacol 2006 62 : 257 259.
10. Ritter JM, Harding I, Warren JB. Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends in Pharmacological Sciences 2009 30 : 503 508.
11. Patrono C, Baigent C. Low dose aspirin, coxibs and other NSAIDs: a clinicalmosaic emerges. Mol Interv 2009 9 : 31 9.
12. Solomon SD et al. Cardiovascular risk of celecoxib in six randomised placebo-controlled trials: the cross trial safety analysis. Circulation 2008 117 : 2104 2113.
13. Nussmeier, NA et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 352 : 1081 1091.
14. Kearney PM et al. Do selective cyclooxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk ofatherothrombosis Meta-analysis of randomised trials BMJ 2006 332 : 1302 1308.
15. Curfman GD et al. Expression of concern. N Engl J Med 2005 353 : 2813 2814.
16. Bresalier RS et al. The Adenomatous Polyp Prevention on Vioxx (APPROVe). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 352 : 1092 1102.
17. Nissen SE. Adverse events of rofecoxib. N Engl J Med 2006 355 : 203 204.
18. Furberg C. Adverse effects of rofecoxib. N Engl J Med 2006 355 : 204.
19. Moore N. No obvious extra cardiovascular risk associated with low-dose NSAIDs. Clin Pharm Therap 2009 advance online publication 6 May doi:10.1038/clpt2009.66.
20. Garcia Rodriguez LA et al. Role of dose potency in the prediction of risk of mycardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. JACC 2008 52 : 1628 1636.
21. Blood pressure lowering treatment trialists' collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. BMJ 2008 336 : 1121 1127.
22. Heart Protection Study Collaboration. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 : 2005 2016.
23. Wheeler BW, Metcalfe C, Gunnell D, Stephens P, Martin RM. Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. Br J Clin Pharmacol 2009 68 : 752 764.
24. Aronoff DM et al. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthesises. Clin Pharmacol Therap 2006 79 : 9.
25. Hinz B et al. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008 22 : 383 390.
26. Li S et al. Acetaminophen: antipyretic or hypothermic in mice? In either case, PGHS-1b (COX-3) is irrelevant Prostaglandin and other lipid mediators 2008 85 : 89 99.
27. Chan AT et al. Nonsteroidal anti-inflammatory drugs, acetaminophen and the risk of cardiovascular events. Circulation 2006 113 : 1578 1587.
28. Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 2009 373 : 1749 1760.